fluorobenzenes has been researched along with Parkinson Disease, Secondary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ansah, TA; Ferguson, MC; Nayyar, T | 1 |
| Angst, J; Frei, M | 1 |
1 trial(s) available for fluorobenzenes and Parkinson Disease, Secondary
| Article | Year |
|---|---|
[The depot neuroleptic agent fluspirilene (author's transl)].
Topics: Basal Ganglia Diseases; Blood Pressure; Chronic Disease; Clinical Trials as Topic; Female; Fluorobenzenes; Fluphenazine; Heart Rate; Humans; Injections, Intramuscular; Male; Parkinson Disease, Secondary; Piperidines; Psychiatric Status Rating Scales; Schizophrenia; Spiro Compounds; Time Factors; Tranquilizing Agents | 1973 |
1 other study(ies) available for fluorobenzenes and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Reverse microdialysis of a 5-HT2A receptor antagonist alters extracellular glutamate levels in the striatum of the MPTP mouse model of Parkinson's disease.
Topics: Animals; Extracellular Space; Fluorobenzenes; Glutamic Acid; Male; Mice; Mice, Inbred C57BL; Microdialysis; MPTP Poisoning; Neostriatum; Parkinson Disease, Secondary; Piperidines; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Synaptosomes | 2014 |